Hicin Pharmaceutical(300584)
Search documents
海辰药业(300584.SZ):部分电解液添加剂产品已向国内头部电解液厂商量产供货
Ge Long Hui· 2025-10-22 07:07
格隆汇10月22日丨海辰药业(300584.SZ)在投资者互动平台表示,公司部分电解液添加剂产品已向国内 头部电解液厂商量产供货,相关进展可见公司定期报告。 ...
短线防风险 84只个股短期均线现死叉
Zheng Quan Shi Bao Wang· 2025-10-20 06:51
Market Overview - As of 14:00, the Shanghai Composite Index is at 3859.80 points, with an increase of 0.52% [1] - The total trading volume of A-shares today is 1,431.28 billion yuan [1] Technical Analysis - A total of 84 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - The stocks with the largest distance between their 5-day and 10-day moving averages include: - Yunnan Zhenye: 5-day MA is -2.45% below the 10-day MA [1] - Qiangli New Materials: 5-day MA is -2.22% below the 10-day MA [1] - Feirongda: 5-day MA is -2.14% below the 10-day MA [1] Individual Stock Performance - Yunnan Zhenye (002428): Today's change is -0.93%, with a 5-day MA of 27.71 yuan and a 10-day MA of 28.41 yuan [1] - Qiangli New Materials (300429): Today's change is +0.53%, with a 5-day MA of 13.95 yuan and a 10-day MA of 14.26 yuan [1] - Feirongda (300602): Today's change is +1.03%, with a 5-day MA of 33.00 yuan and a 10-day MA of 33.72 yuan [1] - Other notable stocks include: - Warner Pharmaceuticals (688799): Today's change is +0.43%, with a 5-day MA of 55.41 yuan [1] - Blue Ying Equipment (300293): Today's change is +0.34%, with a 5-day MA of 24.48 yuan [1] Additional Stock Data - The following stocks also show a downward trend in their 5-day moving averages compared to their 10-day moving averages: - Nanya New Materials (688519): -0.90% change, 5-day MA of 74.18 yuan [1] - Aerospace Morning Light (600501): -2.84% change, 5-day MA of 23.60 yuan [1] - Haichen Pharmaceutical (300584): +1.92% change, 5-day MA of 57.39 yuan [1]
海辰药业:截至10月10日公司股东数为22685户
Zheng Quan Ri Bao Wang· 2025-10-16 09:45
证券日报网讯海辰药业(300584)10月16日在互动平台回答投资者提问时表示,截至10月10日,公司股 东数为22685户。 ...
原料药板块强势 向日葵涨幅居前
Xin Lang Cai Jing· 2025-10-15 03:05
10月15日消息,截止10:45,原料药板块强势,亚太药业涨停,向日葵、海辰药业、博腾股份、华海药 业、金达威等个股涨幅居前。 责任编辑:小浪快报 ...
海辰药业:截至9月30日公司股东数为22415户
Zheng Quan Ri Bao Wang· 2025-10-10 11:48
证券日报网讯海辰药业(300584)10月10日在互动平台回答投资者提问时表示,截至9月30日,公司股 东数为22415户。 ...
化学制药板块10月9日跌0.66%,南新制药领跌,主力资金净流出11.08亿元
Zheng Xing Xing Ye Ri Bao· 2025-10-09 08:54
Market Overview - The chemical pharmaceutical sector experienced a decline of 0.66% on October 9, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haichen Pharmaceutical (300584) with a closing price of 63.81, up 13.76% and a trading volume of 155,800 shares, totaling 973 million yuan [1] - Changshan Pharmaceutical (300255) closed at 49.29, up 8.21% with a trading volume of 394,400 shares, totaling 1.916 billion yuan [1] - Conversely, Nanjing New Pharmaceutical (688189) saw a significant drop of 19.96%, closing at 9.10 with a trading volume of 32,300 shares, totaling 29.426 million yuan [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.108 billion yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 14.6 million yuan from institutional investors, but a net outflow of 14 million yuan from retail investors [3] - Haichen Pharmaceutical recorded a net inflow of 85.3 million yuan from institutional investors, with retail investors showing a net outflow of 68 million yuan [3]
锂电9月洞察:旺季需求上行,板块涨价渐显
SINOLINK SECURITIES· 2025-10-08 11:10
Investment Rating - The report maintains a "Buy" rating for the electric equipment and new energy industry [1] Core Insights - The lithium battery sector is experiencing a seasonal demand increase, with lithium carbonate and lithium hydroxide prices rising by 20% in September [1][6] - In August, domestic wholesale sales of new energy passenger vehicles reached 1.18 million units, reflecting a year-on-year increase of 22% and a month-on-month increase of 10% [1][4] - The report highlights the importance of solid-state battery technology and its potential breakthroughs in addressing interface issues, which are critical for commercialization [3][18] Summary by Sections Monthly Research Insights - The report discusses solutions to solid-solid interface issues in solid-state battery manufacturing, emphasizing the need for breakthroughs in physical, chemical, and mechanical dimensions [3][13] Industry Sentiment Tracking and Review - New energy vehicle sales in August showed strong growth, with China, Europe, and the US leading the market [4][22] - Domestic energy storage installations in August reached 12.6 GWh, a year-on-year increase of 58% [5][28] - The report forecasts a significant increase in lithium battery production in October, with year-on-year growth expected to be between 21% and 50% [5][34] Price and Volume Analysis - Lithium battery material prices are on the rise, with lithium carbonate and lithium hydroxide prices increasing by 20% in September [6][35] - The report notes that the lithium battery supply chain is entering a replenishment phase, with inventory levels rising [39] New Technology Developments - Solid-state batteries and composite current collectors are entering a critical engineering and industrialization phase, with significant orders expected for 2025 [6][44] - The report identifies key investment opportunities in solid-state battery technology, particularly in dry processing and isostatic pressing equipment [18][21] Investment Recommendations - The report recommends focusing on leading companies in the lithium battery sector and those involved in solid-state technology breakthroughs, such as CATL and EVE Energy [7][21]
化学制药板块9月24日涨0.13%,向日葵领涨,主力资金净流入1.49亿元
Zheng Xing Xing Ye Ri Bao· 2025-09-24 08:39
证券之星消息,9月24日化学制药板块较上一交易日上涨0.13%,向日葵领涨。当日上证指数报收于 3853.64,上涨0.83%。深证成指报收于13356.14,上涨1.8%。化学制药板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 8.57 | 20.03% | 300.34万 | | 24.00亿 | | 002020 | 京新药业 | 21.63 | 10.02% | 27.78万 | | 5.81亿 | | 002294 | 信立泰 | 60.24 | 10.01% | 14.80万 | | 8.69% | | 300584 | 海辰药业 | 61.56 | 7.98% | 15.43万 | | 9.31亿 | | 688197 | 首药控股 | 48.28 | 6.93% | 3.02万 | | 1.41亿 | | 688302 | 海创药业 | 55.69 | 6.62% | 4.06万 | | 2.26亿 | | 00 ...
海辰药业:关于公司硫代硫酸钠注射液获得药品注册批件的公告
Zheng Quan Ri Bao· 2025-09-19 15:42
Core Viewpoint - Recently, Haichen Pharmaceutical received approval from the National Medical Products Administration for the drug registration certificate of Sodium Thiosulfate Injection [2] Company Summary - Haichen Pharmaceutical announced the receipt of the drug registration certificate for Sodium Thiosulfate Injection [2]
沪电股份拟筹划发行H股;13连板天普股份称股价存在快速下跌风险丨公告精选
2 1 Shi Ji Jing Ji Bao Dao· 2025-09-19 13:28
Group 1 - Huadian Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] - Cisco Ray's 2022 annual report was found to have inflated revenue by 9.96 million and profit by 7.0054 million, leading to penalties and a change in stock name to ST Cisco Ray [3] - Tianpu Co., Ltd. experienced a 245.20% increase in stock price over 13 consecutive trading days, indicating a risk of rapid decline [4] - ST New Power is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6] - Baoli International intends to invest in semiconductor testing equipment company Hongtai Technology, acquiring 1%-3% equity [7] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Shiqi Future, focusing on smart vision technology [8] Group 2 - SF Holding reported a revenue of 24.787 billion yuan in August, a year-on-year increase of 7.86% [9] - Various companies are involved in share transfers, including Guangli Micro and *ST Tianlong, with plans for significant asset restructuring [11] - Xinwangda's subsidiary aims to establish a storage industry fund with professional investment institutions [12] - Several companies are planning share repurchases, including Shunhao Co. and Lingyun Optics, with adjustments to repurchase plans [18]